Sign in

CIK 0000875045

  • Large accelerated filer

BIOGEN INC.

Sign in to watch
Ticker
BIIB
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
330112644
Phone
+1 617-679-2000
Business address
225 BINNEY STREET, CAMBRIDGE, MA, 02142
Former names
BIOGEN IDEC INC., BIOGEN IDEC INC, IDEC PHARMACEUTICALS CORP / DE, IDEC PHARMACEUTICALS CORP / CA
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2017-06-07 DENNER ALEXANDER J Director Grant or award +1,055 10,029
2017-06-01 Ehlers Michael D EVP, Research and Development Shares withheld for taxes −336 $252.38 $85K 2,768
2017-06-01 Ehlers Michael D EVP, Research and Development Exercise or conversion +1,259 4,027
2017-06-01 Ehlers Michael D EVP, Research and Development Shares withheld for taxes −411 $252.38 $104K 3,616
2017-06-01 Ehlers Michael D EVP, Research and Development Exercise or conversion · Restricted Stock Unit −1,259 6,231
2017-06-01 Ehlers Michael D EVP, Research and Development Other disposition · Restricted Stock Unit −1,235 4,996
2017-05-02 Vounatsos Michel Chief Executive Officer Exercise or conversion +1,736 4,663.46
2017-05-02 Vounatsos Michel Chief Executive Officer Shares withheld for taxes −564 $271.34 $153K 4,099.46
2017-05-02 Vounatsos Michel Chief Executive Officer Exercise or conversion · Restricted Stock Unit −1,736 8,004
2017-05-02 Vounatsos Michel Chief Executive Officer Other disposition · Restricted Stock Unit −1,508 6,496
2017-05-01 Vounatsos Michel Chief Executive Officer Purchase +1,402 $271.35 $380K 2,927.46
2017-04-27 DENNER ALEXANDER J Director Purchase +15,000 $278.58 $4.2M 325,000
2017-04-27 DENNER ALEXANDER J Director Purchase +58,858 $278.48 $16.4M 383,858
2017-04-25 Clancy Paul J Executive VP and CFO Sale −9,892 $290.00 $2.9M 10,813
2017-04-03 Sandrock Alfred EVP CMO Neuro & Neurodegenerat Sale −1,981 $274.08 $543K 7,059.86
2017-03-13 Clancy Paul J Executive VP and CFO Sale −9,891 $291.55 $2.9M 20,705
2017-03-01 McKenzie Paul EVP Pharmaceutical Oper & Tech Exercise or conversion +481 718.44
2017-03-01 McKenzie Paul EVP Pharmaceutical Oper & Tech Shares withheld for taxes −157 $293.26 $46K 561.44
2017-03-01 McKenzie Paul EVP Pharmaceutical Oper & Tech Grant or award +2,730 3,291.44
2017-03-01 McKenzie Paul EVP Pharmaceutical Oper & Tech Exercise or conversion · Restricted Stock Unit −481 2,055

Page 62 of 73 · 1,456 trades